European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots

View source ↗

Summary

EMA recommends changes in how ponatinib (Iclusig) is used to reduce the risk of blood clots in leukemia treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Iclusig (ponatinib)